Anticipated evaluation to include combination therapy featuring treatment regimen of checkpoint inhibition and chemotherapy utilized in cohort 1 of the GOB...
FogPharma®, a clinical-stage biopharmaceutical company dedicated to delivering a new class of therapies that go beyond the limits of currently availabl...
Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that the National...
This innovative therapy, the first and only peptide-formulated, long-lasting neurotoxin of its kind, presents a compelling option for patients and physicia...
Zai Lab Limited announced that the National Medical Products Administration (NMPA) in China has approved the New Drug Application (NDA) for AUGTYRO™ ...
- CX-801 is a dually masked, conditionally activated IFNα2b cytokine designed using the CytomX Probody® Therapeutic Platform - - Phase 1 first-i...
Initial data from 15 patients with relapsed/refractory (r/r) marginal zone lymphoma (MZL) show 13 patients achieved a complete response and one patient ach...
Astellas Pharma and Poseida Therapeutics, Inc. announced that Xyphos Biosciences, Inc., (a wholly owned subsidiary of Astellas, "Xyphos")...
Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, has announced the launch of its enhanced bioassay platform EpiScree...
Transaction provides company with an estimated approximately $128 million in cost savings, including approximately $67 million in clinical de...
EXO Biologics, a clinical-stage biotech and a pioneer in developing exosome-based therapies, announces the successful securing of a t...
BioArctic AB (publ) announced that BioArctic AB and Eisai Co., Ltd., have entered into a research evaluation agreement regarding BAN2802, a potential new t...
Biopharmaceutical contract manufacturer SK pharmteco commits to production, testing, and release of Ferring’s U.S. approved ADSTILADRIN® ...
FibroBiologics, , a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential...
© 2025 Biopharma Boardroom. All Rights Reserved.
